Concert Pharma (CNCE) Announces Results of CTP-656 Phase 1; Demonstrated Superior PK Profile to Kalydeco
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Futures tread higher as more earnings roll in
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises on robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
Brean Capital Raises Price Target on Concert Pharma (CNCE) Following CTP-656 Phase I Trial Results
September 23, 2015 11:07 AM EDTBrean Capital reiterated a Buy rating on Concert Pharmaceuticals (NASDAQ: CNCE), and raised the price target to $25.00 (from $21.00), following phase I results for CTP-656. If the drug is approved, it could compete head to head with Vertex's Kalydeco which Brean Capital expects to generate... More
Aegis Capital Affirms Concert Pharma (CNCE) at 'Buy' Following CTP-656 Phase 1 Data
September 22, 2015 3:58 PM EDTAegis Capital affirms Concert Pharmaceuticals (Nasdaq: CNCE) with a Buy rating and $26 price target after the company announced positive data from a Phase 1 single ascending dose clinical trial of CTP-656.
Analyst Robert LeBoyer offered the following conclusion: These data show changes that are... More
Roth Capital Raises Price Target on Concert Pharma (CNCE) Following CTP-656 Data
September 22, 2015 1:22 PM EDTRoth Capital reiterated a Buy rating on Concert Pharmaceuticals (NASDAQ: CNCE), and raised the price target to $32.00 (from $22.00), following the company's first public clinical data for CTP-656. The data showed an improved profile to Kalydeco. The company is currently planning a single Phase II... More
